As GLP-1 receptor agonists like semaglutide become ubiquitous tools for managing obesity, an urgent clinical gap has emerged: what happens when women conceive while still on these medications? With millions of reproductive-age women now using semaglutide, this question carries immediate real-world stakes for maternal-fetal medicine and obstetric practice.
This retrospective cohort study drew on a large, nationally linked electronic medical record and pharmacy dataset (Truveta) to track pregnancy outcomes across three groups of women with prepregnancy overweight or obesity who delivered between January 2022 and January 2026: those who continued semaglutide into pregnancy (n=429, median in-pregnancy exposure of 44 days), those who discontinued before conception, and matched nonusers (n=2,203). Using 1:1 propensity score matching on key confounders — including prepregnancy BMI, diabetes, and hypertension — followed by logistic and linear regression, the researchers examined gestational weight gain alongside rates of gestational diabetes, preterm birth, pregnancy-related hypertension, intrauterine growth restriction, excessive fetal growth, and cesarean delivery.
Several findings merit careful interpretation. Gestational weight gain was measurably different in pregnancy-exposed users, a finding consistent with semaglutide's appetite-suppressing mechanism persisting into the first trimester. Whether this translates to clinically meaningful differences in fetal growth trajectories remains a nuanced question that this dataset is only partially equipped to answer. The observational design, while strengthened by propensity matching, cannot rule out residual confounding from factors such as dietary behavior or comorbidity severity. The pregnancy-exposed group's median exposure of just 44 days suggests most women discontinued relatively early, limiting inference about prolonged fetal exposure. Animal teratogenicity data for semaglutide remain a background concern, though direct translation to humans is uncertain. Overall, this study is an important early contribution to a data-sparse area, but its retrospective nature and modest exposed-group size mean clinical guidance on semaglutide discontinuation timing should await larger prospective work.